Literature DB >> 12811988

Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene.

Juan Carlos Arango Lasprilla1, Jaime Iglesias, Francisco Lopera.   

Abstract

In Antioquia, Colombia, investigators have recently discovered the largest family with the E280A mutation in the presenilin 1 gene that causes one type of familial Alzheimer's disease (FAD). The current study compares two groups within this family: those diagnosed with Alzheimer's disease (AD) in its early stage (nine subjects) and relatives (carriers) who did not show any signs of dementia (nine subjects). A battery of the following neuropsychological tests was administered to subjects in both groups: the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), a Phonological Verbal Fluency test, the Visual "A" Cancellation Test, memory of three phrases, the Rey-Osterrieth Complex Figure, and the Trail Making Test Part A. Statistical analyses of the average test scores of each group showed that the AD group scored significantly (p < 0.01 or p < 0.05) lower on 29 of the 43 neuropsychological variables measured (67 percent). Therefore, this specific battery was useful in discriminating subjects with AD from their healthy relatives who are carriers of the disease. The AD group as a whole presented slight dementia with predominant deficits in memory, language, praxis, and attention. This profile is similar to those reported in subjects with sporadic AD in its early stage and confirms the findings found in other neuropsychological studies of subjects with FAD linked to mutations in chromosome 14.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811988     DOI: 10.1177/153331750301800306

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  8 in total

1.  Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease.

Authors:  Yakeel T Quiroz; Andrew E Budson; Kim Celone; Adriana Ruiz; Randall Newmark; Gabriel Castrillón; Francisco Lopera; Chantal E Stern
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

2.  Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials.

Authors:  J B Langbaum; S Hendrix; N Ayutyanont; D A Bennett; R C Shah; L L Barnes; F Lopera; E M Reiman; P N Tariot
Journal:  J Prev Alzheimers Dis       Date:  2015-03

3.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

Review 4.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

6.  Linear Combinations of Multiple Outcome Measures to Improve the Power of Efficacy Analysis ---Application to Clinical Trials on Early Stage Alzheimer Disease.

Authors:  Chengjie Xiong; Jingqin Luo; John C Morris; Randall Bateman
Journal:  Biostat Epidemiol       Date:  2017-06-02

7.  ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A PS-1 mutation.

Authors:  María A Bobes; Yuriem Fernández García; Francisco Lopera; Yakeel T Quiroz; Lídice Galán; Mayrim Vega; Nelson Trujillo; Mitchell Valdes-Sosa; Pedro Valdes-Sosa
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

8.  Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Authors:  Gerda G Fillenbaum; Gerald van Belle; John C Morris; Richard C Mohs; Suzanne S Mirra; Patricia C Davis; Pierre N Tariot; Jeremy M Silverman; Christopher M Clark; Kathleen A Welsh-Bohmer; Albert Heyman
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.